Instead of true, de novo drug discovery ... But it’s not AI,” one antibody researcher told STAT. Scientists are increasingly concerned that the Trump administration’s cost-cutting ...

Trials in China usually recruit patients faster than in the west because of the country’s large pool of people who have not yet taken drugs for their condition and who are keen to participate in ...

Figure 1: Antibody design to improve homogeneity ... Thus, decreasing costs is an important part of drug development. The IgG-based biotherapeutic agents that have been approved in the past ...

After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and ...

Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...

The European Commission (EC) has approved catumaxomab, making it the only approved drug therapy for malignant ascites (MA) for patients living with this debilitating condition across Europe.

In the past two years, the Food and Drug Administration has approved two novel Alzheimer's therapies, based on data from ...